The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

The unique challenges, and need for awareness, of age-related macular degeneration (AMD) is now formally recognized in Canada ...

Novel macular degeneration treatments are expected to fuel market ... In September 2022, Bayer will present new cardiorenal results for Kerendia in individuals with early-stage chronic kidney ...

American Academy of Ophthalmology. New treatments for age-related macular degeneration. National Library of Medicine: MedlinePlus. Age-related macular degeneration. Vakharia P, Eichenbaum D.

Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in ...

Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.

In response to the TGA's approval of a new drug to treat macular degeneration, UNSW researcher Dr Lisa Nivison-Smith provides context about the ...

The FDA approved Susvimo for the treatment of diabetic macular edema, according to a press release. The decision was supported by positive 1-year data from the phase 3 Pagoda study, in which Susvimo ...

People who are of European descent may be more at risk of age-related macular degeneration than those of African or Hispanic ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...